Seroprevalence of Toxoplasma gondii and Borrelia burgdorferi infections in patients with multiple sclerosis in Poland.
Borrelia
Toxoplasma
Lyme borreliosis
Lyme disease
Multiple sclerosis
Toxoplasmosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 05 2024
14 05 2024
Historique:
received:
08
01
2024
accepted:
08
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous system that affects mainly young people. It is believed that the autoimmune process observed in the pathogenesis of MS is influenced by a complex interaction between genetic and environmental factors, including infectious agents. The results of this study suggest the protective role of Toxoplasma gondii infections in MS. Interestingly, high Toxoplasma IgM seropositivity in MS patients receiving immunomodulatory drugs (IMDs) was identified. On the other hand, Borrelia infections seem to be positively associated with MS. Although the interpretation of our results is limited by the retrospective nature of the studies, the results strongly indicate that further experimental and clinical studies are needed to explain the role of infectious agents in the development and pathophysiological mechanisms of MS.
Identifiants
pubmed: 38744898
doi: 10.1038/s41598-024-61714-y
pii: 10.1038/s41598-024-61714-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11015Subventions
Organisme : the Foundation for Polish Science
ID : TEAM TECH/2017-4/22
Organisme : the Ministry of Science and Higher Education, Poland
ID : Excellence Initiative - Research University (2020-2026)" in Actions IV.3.1
Informations de copyright
© 2024. The Author(s).
Références
Ebers, G. C. Environmental factors and multiple sclerosis. Lancet Neurol. 7(3), 268–277. https://doi.org/10.1016/S1474-4422(08)70042-5 (2008).
doi: 10.1016/S1474-4422(08)70042-5
pubmed: 18275928
Ramagopalan, S. V., Deluca, G. C., Degenhardt, A. & Ebers, G. C. The genetics of clinical outcome in multiple sclerosis. J. Neuroimmunol. 201–202, 183–199 (2008).
doi: 10.1016/j.jneuroim.2008.02.016
pubmed: 18632165
Correale, J. & Gaitán, M. I. Multiple sclerosis and environmental factors: The role of vitamin D, parasites, and Epstein-Barr virus infection. Acta Neurol. Scand. 132(199), 46–55. https://doi.org/10.1111/ane.12431 (2015).
doi: 10.1111/ane.12431
pubmed: 26046559
Ascherio, A. et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA 286(24), 3083–3088. https://doi.org/10.1001/jama.286.24.3083 (2001).
doi: 10.1001/jama.286.24.3083
pubmed: 11754673
Versini, M. et al. Unraveling the hygiene hypothesis of helminthes and autoimmunity: Origins, pathophysiology, and clinical applications. BMC Med. 13, 81. https://doi.org/10.1186/s12916-015-0306-7 (2015).
doi: 10.1186/s12916-015-0306-7
pubmed: 25879741
pmcid: 4396177
Robert-Gangneux, F. & Dardé, M. L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin. Microbiol. Rev. 25(2), 264–296. https://doi.org/10.1128/CMR.05013-11 (2012).
doi: 10.1128/CMR.05013-11
pubmed: 22491772
pmcid: 3346298
Shapira, Y., Agmon-Levin, N. & Shoenfeld, Y. Defining and analyzing geoepidemiology and human autoimmunity. J. Autoimmun. 34(3), J168–J177. https://doi.org/10.1016/j.jaut.2009.11.018 (2010).
doi: 10.1016/j.jaut.2009.11.018
pubmed: 20034761
Miman, O., Kusbeci, O. Y., Aktepe, O. C. & Cetinkaya, Z. The probable relation between Toxoplasma gondii and Parkinson’s disease. Neurosci. Lett. 475(3), 129–131. https://doi.org/10.1016/j.neulet.2010.03.057 (2010).
doi: 10.1016/j.neulet.2010.03.057
pubmed: 20350582
Kusbeci, O. Y., Miman, O., Yaman, M., Aktepe, O. C. & Yazar, S. Could Toxoplasma gondii have any role in Alzheimer disease?. Alzheimer Dis. Assoc. Disord. 25(1), 1–3. https://doi.org/10.1097/WAD.0b013e3181f73bc2 (2011).
doi: 10.1097/WAD.0b013e3181f73bc2
pubmed: 20921875
Fischer, S. et al. Toxoplasma gondii: Bystander or cofactor in rheumatoid arthritis. Immunol. Res. 56(2–3), 287–92. https://doi.org/10.1007/s12026-013-8402-2 (2013).
doi: 10.1007/s12026-013-8402-2
pubmed: 23553228
Pearce, B. D., Kruszon-Moran, D. & Jones, J. L. The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol. Psychiatry 72(4), 290–295. https://doi.org/10.1016/j.biopsych.2012.01.003 (2012).
doi: 10.1016/j.biopsych.2012.01.003
pubmed: 22325983
pmcid: 4750371
Alvarado-Esquivel, C. et al. Toxoplasma gondii infection and depression: A case–control seroprevalence study. Eur. J. Microbiol. Immunol. 6(2), 85–89. https://doi.org/10.1556/1886.2016.00010 (2016).
doi: 10.1556/1886.2016.00010
Koskderelioglu, A., Afsar, I., Pektas, B. & Gedizlioglu, M. Is Toxoplasma gondii infection protective against multiple sclerosis risk?. Mult Scler. Relat. Disord. 15, 7–10. https://doi.org/10.1016/j.msard.2017.04.004 (2017).
doi: 10.1016/j.msard.2017.04.004
pubmed: 28641775
Cicero, C. E. et al. Toxoplasma gondii and multiple sclerosis: A systematic review and meta-analysis. Eur. J. Neurol. 28(12), 4251–4257. https://doi.org/10.1111/ene.15055 (2021).
doi: 10.1111/ene.15055
pubmed: 34374174
Nicoletti, A. et al. Toxoplasma gondii and multiple sclerosis: A population-based case-control study. Sci. Rep. 10(1), 18855. https://doi.org/10.1038/s41598-020-75830-y (2020).
doi: 10.1038/s41598-020-75830-y
pubmed: 33139781
pmcid: 7606604
Stascheit, F., Paul, F., Harms, L. & Rosche, B. Toxoplasma gondii seropositivity is negatively associated with multiple sclerosis. J. Neuroimmunol. 285, 119–124. https://doi.org/10.1016/j.jneuroim.2015.05.011 (2015).
doi: 10.1016/j.jneuroim.2015.05.011
pubmed: 26198927
Oruç, S. et al. Relationship of Toxoplasma gondii exposure with multiple sclerosis. Eur. J. Gen. Med. 13(1), 58–63. https://doi.org/10.15197/ejgm.01429 (2016).
doi: 10.15197/ejgm.01429
Saberi, R. et al. Is Toxoplasma gondii playing a positive role in multiple sclerosis risk? A systematic review and meta-analysis. J. Neuroimmunol. 322, 57–62. https://doi.org/10.1016/j.jneuroim.2018.06.011 (2018).
doi: 10.1016/j.jneuroim.2018.06.011
pubmed: 29954625
Shapira, Y. et al. Prevalence of anti-Toxoplasma antibodies in patients with autoimmune diseases. J. Autoimmun. 39(1–2), 112–116 (2012).
doi: 10.1016/j.jaut.2012.01.001
pubmed: 22297145
Lindgren, E., & Jaenson, T. G. T. Lyme borreliosis in Europe. in Influences of Climate and Climate Change, Epidemiology, Ecology and Adaptation Measures (World Health Organization, 2006).
Garkowski, A. et al. Cerebrovascular manifestations of lyme neuroborreliosis—A systematic review of published cases. Front. Neurol. 8, 146. https://doi.org/10.3389/fneur.2017.00146 (2017).
doi: 10.3389/fneur.2017.00146
pubmed: 28473801
pmcid: 5397664
Drozdowski, W. Multifocal central nervous system lesions—Multiple sclerosis or neuroborreliosis?. Przegl. Epidemiol. 60(Suppl 1), 39–45 (2006).
pubmed: 16909774
MacLean, G., Cook, P., Lindsay, L. R., Hatchette, T. F. & Webster, D. Low seroprevalence of lyme disease among multiple sclerosis patients in New Brunswick. Can. J. Neurol. Sci. 47(6), 842–844. https://doi.org/10.1017/cjn.2020.129 (2020).
doi: 10.1017/cjn.2020.129
pubmed: 32594964
di Bella, P. et al. The presence of anti-Borrelia burgdorferi antibodies in a group of multiple sclerosis patients in eastern Sicily. Preliminary data. Acta Neurol. 15(4), 253–257 (1993).
Lana-Peixoto, M. A. Multiple sclerosis and positive Lyme serology. Arq Neuropsiquiatr. 52(4), 566–71. https://doi.org/10.1590/s0004-282x1994000400019 (1994).
doi: 10.1590/s0004-282x1994000400019
pubmed: 7611954
Martin, R. et al. Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease. J. Autoimmun. 16(3), 187–192. https://doi.org/10.1006/jaut.2000.0501 (2001).
doi: 10.1006/jaut.2000.0501
pubmed: 11334482
Forrester, J. D., Kugeler, K. J., Perea, A. E., Pastula, D. M. & Mead, P. S. No geographic correlation between lyme disease and death due to 4 neurodegenerative disorders, United States, 2001–2010. Emerg. Infect. Dis. 21(11), 2036–2039. https://doi.org/10.3201/eid2111.150778 (2015).
doi: 10.3201/eid2111.150778
pubmed: 26488307
pmcid: 4622257
The Multiple Sclerosis International Federation, Atlas of MS, 3rd edn., September 2020. https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf .
The Polish Ministry of Health. https://ezdrowie.gov.pl/portal/home/badania-i-dane/zdrowe-dane/raporty/nfz-o-zdrowiu-stwardnienie-rozsiane .
Chmielewska-Badora, J., Cisak, E. & Dutkiewicz, J. Lyme borreliosis and multiple sclerosis: Any connection? A seroepidemic study. Ann. Agric. Environ. Med. 7(2), 141–143 (2000).
pubmed: 11153045
Lublin, F. D. & Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 46(4), 907–11. https://doi.org/10.1212/wnl.46.4.907 (1996).
doi: 10.1212/wnl.46.4.907
pubmed: 8780061
Moniuszko-Malinowska, A. et al. Recommendations for the diagnosis and treatment of Lyme borreliosis of the Polish Society of epidemiologists and infectious disease physicians. Przegl. Epidemiol. 77(3), 261–278. https://doi.org/10.32394/pe.77.25 (2023).
doi: 10.32394/pe.77.25
pubmed: 38328896
Stanek, G. et al. Lyme borreliosis: Clinical case definitions for diagnosis and management in Europe. Clin. Microbiol. Infect. 17(1), 69–79. https://doi.org/10.1111/j.1469-0691.2010.03175.x (2011).
doi: 10.1111/j.1469-0691.2010.03175.x
pubmed: 20132258
Jankovic, D. et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204(2), 273–283. https://doi.org/10.1084/jem.20062175 (2007).
doi: 10.1084/jem.20062175
pubmed: 17283209
pmcid: 2118735
Ham, D. W. et al. Chronic Toxoplasma gondii infection alleviates experimental autoimmune encephalomyelitis by the immune regulation inducing reduction in IL-17A/Th17 via upregulation of SOCS3. Neurotherapeutics 18(1), 430–447. https://doi.org/10.1007/s13311-020-00957-9 (2021).
doi: 10.1007/s13311-020-00957-9
pubmed: 33205383
Gras, L., Gilbert, R. E., Wallon, M., Peyron, F. & Cortina-Borja, M. Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: Implications for clinical practice and cross-sectional incidence studies. Epidemiol. Infect. 132(3), 541–548. https://doi.org/10.1017/s0950268803001948 (2004).
doi: 10.1017/s0950268803001948
pubmed: 15188723
pmcid: 2870133
Celius, E. G. Infections in patients with multiple sclerosis: Implications for disease-modifying therapy. Acta Neurol. Scand. 136(Suppl 201), 34–36. https://doi.org/10.1111/ane.12835 (2017).
doi: 10.1111/ane.12835
pubmed: 29068490
Epstein, D. J., Dunn, J. & Deresinski, S. Infectious complications of multiple sclerosis therapies: Implications for screening, prophylaxis, and management. Open Forum Infect. Dis. 5(8), ofy174. https://doi.org/10.1093/ofid/ofy174 (2018).
doi: 10.1093/ofid/ofy174
pubmed: 30094293
pmcid: 6080056
Enriquez-Marulanda, A. et al. Cerebral toxoplasmosis in an MS patient receiving Fingolimod. Mult Scler. Relat. Disord. 18, 106–108. https://doi.org/10.1016/j.msard.2017.05.004 (2017).
doi: 10.1016/j.msard.2017.05.004
pubmed: 29141790
Kieseier, B. C. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 25(6), 491–502. https://doi.org/10.2165/11591110-000000000-00000 (2011).
doi: 10.2165/11591110-000000000-00000
pubmed: 21649449
Neuhaus, O., Farina, C., Wekerle, H. & Hohlfeld, R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56(6), 702–708. https://doi.org/10.1212/wnl.56.6.702 (2001).
doi: 10.1212/wnl.56.6.702
pubmed: 11288751
Linker, R. A. & Gold, R. Dimethyl fumarate for treatment of multiple sclerosis: Mechanism of action, effectiveness, and side effects. Curr. Neurol. Neurosci. Rep. 13(11), 394. https://doi.org/10.1007/s11910-013-0394-8 (2013).
doi: 10.1007/s11910-013-0394-8
pubmed: 24061646
Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J. & Wiendl, H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74(6), 659–674. https://doi.org/10.1007/s40265-014-0212-x (2014).
doi: 10.1007/s40265-014-0212-x
pubmed: 24740824
pmcid: 4003395
Zecca, C., Nessi, F., Bernasconi, E. & Gobbi, C. Ocular toxoplasmosis during natalizumab treatment. Neurology 73(17), 1418–1419. https://doi.org/10.1212/WNL.0b013e3181bd114f (2009).
doi: 10.1212/WNL.0b013e3181bd114f
pubmed: 19776379
Grebenciucova, E., Reder, A. T. & Bernard, J. T. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler. Relat. Disord. 9, 158–162. https://doi.org/10.1016/j.msard.2016.07.015 (2016).
doi: 10.1016/j.msard.2016.07.015
pubmed: 27645366
Brownlee, W. J. & Chataway, J. Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome. Mult Sclerosis 23(6), 876–877. https://doi.org/10.1177/1352458517693440 (2017).
doi: 10.1177/1352458517693440
Yann, K. et al. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis. Mult Scler. Relat. Disord. 14, 1–3. https://doi.org/10.1016/j.msard.2017.03.001 (2017).
doi: 10.1016/j.msard.2017.03.001
pubmed: 28619423
Karussis, D., Weiner, H. L. & Abramsky, O. Multiple sclerosis vs Lyme disease: A case presentation to a discussant and a review of the literature. Mult Sclerosis 5(6), 395–402. https://doi.org/10.1177/135245859900500i605 (1999).
doi: 10.1177/135245859900500i605
Fritzsche, M. Geographical and seasonal correlation of multiple sclerosis to sporadic schizophrenia. Int. J. Health Geogr. 1(1), 5. https://doi.org/10.1186/1476-072x-1-5 (2002).
doi: 10.1186/1476-072x-1-5
pubmed: 12537588
pmcid: 149400
Wolfson, C. & Talbot, P. Bacterial infection as a cause of multiple sclerosis. Lancet 360(9330), 352–353. https://doi.org/10.1016/S0140-6736(02)09603-4 (2002).
doi: 10.1016/S0140-6736(02)09603-4
pubmed: 12241771
Schmutzhard, E., Pohl, P. & Stanek, G. Borrelia burgdorferi antibodies in patients with relapsing/remitting form and chronic progressive form of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 51(9), 1215–1218. https://doi.org/10.1136/jnnp.51.9.1215 (1988).
doi: 10.1136/jnnp.51.9.1215
pubmed: 3225603
pmcid: 1033030
Wojciechowska-Koszko, I. et al. Cross-reactive results in serological tests for borreliosis in patients with active viral infections. Pathogens 11(2), 203. https://doi.org/10.3390/pathogens11020203 (2022).
doi: 10.3390/pathogens11020203
pubmed: 35215146
pmcid: 8879713
Kodym, P. et al. Serological diagnostics of Lyme borreliosis: Comparison of universal and Borrelia species-specific tests based on whole-cell and recombinant antigens. J. Clin. Microbiol. 56, e00601-e618. https://doi.org/10.1128/jcm.00601-18 (2018).
doi: 10.1128/jcm.00601-18
pubmed: 30185509
pmcid: 6204684
Dong, Y. et al. Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: A systematic review and meta-analysis. BMJ Glob. Health 7(6), e007744. https://doi.org/10.1136/bmjgh-2021-007744 (2022).
doi: 10.1136/bmjgh-2021-007744
pubmed: 35697507
pmcid: 9185477